Corvus Pharma (NASDAQ:CRVS) Stock, Quote.Headers.trade-ideas

Corvus Pharma

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

CRVS

CWST

NEGG

SANA

Casella Waste Systems, SES AI And Other Big Stocks Moving Lower In Wednesday&#39;s Pre-Market Session

Alcoa WC

Intraday Update

ASND

BLCO

FTEL

JBDI

LSCC

NUVL

SATS

SSYS

VSAT

Alcoa, Lattice Semiconductor, Stratasys And Other Big Stocks Moving Higher On Monday

Fortinet_logo

CYRX

DZSI

FTNT

LITM

LUMN

MYND

NVRO

PRCH

SCPX

STEM

SWIM

TLIS

UPST

VBIV

XAIR

ZCMD

Why Fortinet Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharmaceuticals Inc

U.S. stock futures were higher this morning, with the Dow futures gaining around 50 points on Wednesday.
Shares of Casella Waste Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWST#NASDAQ">CWST</a>) fell sharply in today's pre-market trading after the company announced a proposed public offering of <a href="https://widgets.benzinga.com/quote/CWST/news">Class A common stock</a>.
Casella Waste Systems shares fell 3.3% to $103.21 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>XCHG Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCH#NASDAQ">XCH</a>) shares dipped 15.3% to $9.40 in pre-market trading after gaining 34% on Tuesday.</li>
<li>SES AI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) shares fell 6% to $0.9220 in pre-market trading. SES AI, on Tuesday, announced a collaboration with NVIDIA, Crusoe and Supermicro on AI for scientific initiative to accelerate material discovery in electric transportation.</li>
<li>Newegg Commerce, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEGG#NASDAQ">NEGG</a>) shares declined 4% to $0.83 in pre-market trading after jumping around 15% on Tuesday.</li>
<li>Corvus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) shares fell 3.6% to $5.30 in pre-market trading after declining 5% on Tuesday. Ladenburg, on Monday, maintained a Buy rating on the stock and raised its price target from $12 to $21.</li>
<li>Medical Properties Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPW#NYSE">MPW</a>) shares fell 3.2% to $6.04 in pre-market trading.</li>
<li>Harmony Gold Mining Company Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMY#NYSE">HMY</a>) shares fell 2.9% to $9.79 in pre-market trading.</li>
<li>Sana Biotechnology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) shares declined 2.6% to $4.19 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/09/40898216/cramer-hewlett-packard-is-a-very-inexpensive-stock-likes-this-big-tech-stock">Cramer: Hewlett Packard Is A &#8216;Very Inexpensive&#8217; Stock, Likes This Big Tech Stock</a></li>
</ul>

Casella Waste Systems, SES AI And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

WIIM

Corvus Pharmaceuticals shares are trading higher after Ladenburg maintained a Buy rating on the stock and raised its price target from $12 to $21.

Ladenburg Thalmann analyst Aydin Huseynov maintains Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) with a Buy and raises the price target from $12 to $21.

Price Target

Analyst Ratings

Ladenburg Thalmann Maintains Buy on Corvus Pharma, Raises Price Target to $21

U.S. stocks were mixed, with the Dow Jones index gaining around 200 points on Monday.
Shares of Alcoa Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AA#NYSE">AA</a>) rose sharply during Monday's session after the company agreed to sell its 25.1% joint venture stake in Ma&#8217;aden for $1.1 billion, including $950 million <a href="https://www.benzinga.com/markets/equities/24/09/40873786/alcoa-pockets-1-1b-from-saudi-joint-venture-sale-details">in Ma&#8217;aden shares.</a>
Alcoa shares jumped 6.5% to $34.63 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Ascendis Pharma A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) shares jumped 19.8% to $142.76 after the company announced topline data from its pivotal approach trial of Transcon CNP (Navepegritide).</li>
<li>Bausch + Lomb Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NASDAQ">BLCO</a>) shares gained 15% to $17.86. Needham reiterated a Hold rating on Bausch &amp; Lomb.</li>
<li>Nuvalent, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVL#NASDAQ">NUVL</a>) climbed 12.8% to $98.70 after the company highlighted results for its ROS1 and ALK-Positive NSCLC programs and accelerated its development timeline. Also, the company announced a $350 million public offering and multiple firms raised their respective price targets on the stock.</li>
<li>Fitell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) gained 12.5% to $17.75.</li>
<li>JBDI Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBDI#NASDAQ">JBDI</a>) jumped 11.1% to $29.38.</li>
<li>Lattice Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) surged 10.3% to $49.46. Lattice Semiconductor appointed Ford Tamer as CEO, effective immediately.</li>
<li>EchoStar Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATS#NASDAQ">SATS</a>) rose 8.4% to $26.33. Morgan Stanley, on Friday, raised its price target on the stock from $14 to $20.</li>
<li>Stratasys Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSYS#NASDAQ">SSYS</a>) rose 7.9% to $7.61 after the company authorized a share repurchase program of up to $50 million.</li>
<li>Corvus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) gained 7.5% to $5.48. The announced it initiated the registrational Phase 3 clinical trial of Soquelitinib for patients with relapsed or refractory peripheral T-cell lymphoma.</li>
<li>Viasat, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSAT#NASDAQ">VSAT</a>) rose 6.3% to $13.57.</li>
<li>Hertz Global Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>) rose 5.5% to $3.1650.</li>
<li>Sprouts Farmers Market, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>) gained 4.2% to $106.42. Evercore ISI Group analyst Michael Morris upgraded Sprouts Farmers Market from In-Line to Outperform and raised the price target from $96 to $120.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/24/09/40876800/this-analyst-with-86-accuracy-rate-sees-around-9-upside-in-rh-here-are-5-stock-picks-for-last-week-f"> </a>
<ul>
<li><a href="https://www.benzinga.com/24/09/40876800/this-analyst-with-86-accuracy-rate-sees-around-9-upside-in-rh-here-are-5-stock-picks-for-last-week-f">This Analyst With 86% Accuracy Rate Sees Around 9% Upside In RH &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Corvus Pharmaceuticals shares are trading higher after the company announced it initiated the registrational Phase 3 clinical trial of Soquelitinib for patients with relapsed or refractory peripheral T-cell lymphoma.

Soquelitinib is a potential first-in-class ITK inhibitor with broad potential in cancer and immune diseases &nbsp;
There are currently no fully approved agents for the treatment of relapsed PTCL and soquelitinib has been granted Orphan Drug Designation and Fast Track Designation by the FDA
BURLINGAME, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>), a clinical-stage biopharmaceutical company, today announced that it has initiated a registrational Phase 3 clinical trial of soquelitinib for patients with relapsed/refractory peripheral T-cell lymphoma (PTCL). The clinical trial is a randomized, controlled study that will evaluate the efficacy and safety of soquelitinib compared to standard of care chemotherapy.

Biotech

General

Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial Of Soquelitinib For Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

Corvus Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 EPS results.

Shares of Fortinet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) rose sharply in today's pre-market trading after the company reported better-than-expected second-quarter financial results and<a href="https://www.benzinga.com/news/earnings/24/08/40203474/fortinet-q2-earnings-revenue-beat-eps-beat-strong-guidance-and-more"> issued guidance above estimates.</a>
Fortinet's second-quarter revenue increased 11% year-over-year to $1.43 billion, beating consensus estimates of $1.403 billion. The cybersecurity company reported second-quarter adjusted earnings of 57 cents per share, beating analyst estimates of 41 cents per share.
Fortinet shares jumped 17% to $65.29 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Richtech Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RR#NASDAQ">RR</a>) rose 68.1% to $0.6220 in today's pre-market trading after dipping around 74% on Tuesday.</li>
<li>Lumen Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) gained 43% to $7.15 in pre-market trading after the company reported better-than-expected second-quarter revenue results.</li>
<li>Zhongchao Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCMD#NASDAQ">ZCMD</a>) gained 34.2% to $1.65 in pre-market trading.</li>
<li>Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) jumped 24% to $29.60 in pre-market trading after the company reported better-than-expected second-quarter financial results and issued third-quarter revenue guidance above estimates.</li>
<li>Latham Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) shares gained 20.6% to $3.75 in pre-market trading after the company reported better-than-expected second-quarter financial results and raised its FY24 revenue guidance above estimates. Additionally, the company announced an acquisition of Coverstar Central.</li>
<li>Mynd.ai, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYND#NYSE">MYND</a>) shares rose 15.9% to $2.55 in pre-market trading after falling around 7% on Tuesday.</li>
<li>Beyond Air, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) shares rose 14.3% to $0.5770 in pre-market trading after the company reported better-than-expected quarterly EPS results.</li>
<li>Snow Lake Resources Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITM#NASDAQ">LITM</a>) gained 12.8% to $0.5756 in pre-market trading after jumping around 13% on Tuesday.</li>
<li>Corvus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) shares gained 10% to $3.30 in pre-market trading after the company reported a narrower-than-expected quarterly loss.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Scorpius Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCPX#NYSE">SCPX</a>) shares dipped 77% to $1.30 in pre-market trading after gaining 19% on Tuesday. Scorpius announced that it has surpassed $100 million in near-term business development opportunities across government and commercial sectors.</li>
<li>Talis Biomedical Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLIS#NASDAQ">TLIS</a>) shares declined 52.7% to $4.25 in pre-market trading after the company initiated a board restructuring.</li>
<li>Porch Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCH#NASDAQ">PRCH</a>) declined 38.2% to $1.07 in pre-market trading after reporting weak quarterly results.</li>
<li>Stem, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) shares declined 37.1% to $0.6274 in pre-market trading after the company reported mixed second-quarter financial results.</li>
<li>Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares fell 36.2% to $6.27 in pre-market trading after posting a loss for the second quarter.</li>
<li>DZS Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DZSI#NASDAQ">DZSI</a>) fell 36.2% to $0.66 pre-market trading after the company announced it received a delisting notice from the Nasdaq.</li>
<li>VBI Vaccines Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBIV#NASDAQ">VBIV</a>) fell 32.2% to $0.09 in today's pre-market trading after jumping 111% on Tuesday.</li>
<li>Nevro Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) shares fell 31.1% to $5.99 in pre-market trading after the company reported worse-than-expected second-quarter sales results.</li>
<li>Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) fell 24.5% to $2.90 in pre-market trading after declining around 11% on Tuesday.</li>
<li>Cryoport, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) shares fell 23.5% to $5.95 in pre-market trading after posting weak quarterly sales.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40194186/top-4-materials-stocks-which-could-rescue-your-portfolio-this-month">Top 4 Materials Stocks Which Could Rescue Your Portfolio This Month</a></li>
</ul>

Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.12) by 41.67 percent. This is a 50 percent increase over losses of $(0.14) per share from the same period last year.

Earnings

Earnings Beats

Corvus Pharma Q2 EPS $(0.07) Beats $(0.12) Estimate

Corvus Pharmaceuticals Announces FDA Fast Track Designation For Soquelitinib In Treatment Of Relapsed Or Refractory PTCL; Phase 3 Clinical Trial To Begin Initial Enrollment In Q3 2024

Corvus Pharmaceuticals Announces Publication In Science Signaling Demonstrating ITK Inhibition By Soquelitinib Induces Anti-Inflammatory Treg Cells; Study Highlights Potential For Treating Inflammatory Autoimmune And Allergic Diseases

Corvus Pharmaceuticals shares are trading lower after the company reported Q1 financial results.

Oppenheimer analyst Jeff Jones maintains Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) with a Outperform and raises the price target from $7 to $8.

Oppenheimer Maintains Outperform on Corvus Pharma, Raises Price Target to $8

Guidance

Corvus Pharma Expects FY24 Net Cash Used In Operating Activities ~$24M-$27M, Resulting In Projected Cash Balance Of $31M-$34M At Dec. 31, 2024; Expects Cash To Find Operations Into Q4 2025

Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) reported quarterly losses of $(0.12) per share which met the analyst consensus estimate.

Corvus Pharma Q1 2024 GAAP EPS $(0.12), Inline

Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today announced that it has entered into a securities purchase agreement with new and existing investors to raise approximately $30.6 million dollars in aggregate gross proceeds through the sale of shares of its common stock, par value $0.0001 per share (the "Common Stock") and pre-funded warrants to purchase Common Stock in lieu thereof (the "Pre-Funded Warrants"), and accompanying common warrants to purchase Common Stock (or Pre-Funded warrants in lieu thereof) (the "Common Warrants," and together with the Common Stock and Pre-Funded Warrants, the "Securities"), excluding the proceeds, if any, from the exercise of the Pre-Funded Warrants and the Common Warrants and before deducting offering expenses. &nbsp;
The offering includes participation from health-care dedicated investors including Point72, Samlyn Capital, Armistice Capital, OrbiMed, Puissance Capital and Altamont Pharmaceutical Holdings, and other existing investors including Richard Miller, the Company's chief executive officer.
The purchase and sale will be completed via a registered direct offering of 13,512,699 shares of Common Stock and accompanying Common Warrants to purchase 13,078,509 shares of Common Stock (or Pre-Funded Warrants in lieu thereof) at a combined offering price of $1.7312 per Share, and Pre-Funded Warrants to purchase 4,144,085 shares of Common Stock and accompanying Common Warrants to purchase 4,010,927 shares of Common Stock (or Pre-Funded Warrants in lieu thereof) at a combined offering price of $1.7311 per share underlying each Pre-Funded Warrant and Common Warrant, which equals the offering price per&nbsp;share of the Common Stock&nbsp;and Common Warrant less the $0.0001 exercise price per share of the Pre-Funded Warrants. The Pre-Funded Warrants have an exercise price of $0.0001 per share of Common Stock and are exercisable at any time after the date of issuance, subject to certain ownership limitations. The Common Warrants have an exercise price of $3.50 per share of Common Stock (or $3.4999 per Pre-Funded Warrant in lieu thereof) and are exercisable at any time after the date of issuance, subject to certain ownership limitations, and expire on June 30, 2025.&nbsp;&nbsp;
All of the Securities are being offered by Corvus. The offering is expected to close on or about May 6, 2024, subject to the satisfaction of customary closing conditions. Since the offering of the Securities was made without an underwriter or a placement agent, the Company will not be paying any underwriting discounts or placement agent fees in connection with the offering.

Offerings

Corvus Pharmaceuticals Announces Pricing Of $30.6M Registered Direct Offering

<h3>Gainers</h3>
<ul>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares rose 25.3% to $0.11 during Tuesday's after-market session. The company's market cap stands at $31.1 million. </li>
<li>aTyr Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIFE#NASDAQ">LIFE</a>) shares rose 10.45% to $1.9. The company's market cap stands at $128.7 million. </li>
<li>Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) shares increased by 7.36% to $1.75. The market value of their outstanding shares is at $85.8 million. </li>
<li>ImmuCell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCC#NASDAQ">ICCC</a>) shares increased by 7.27% to $5.6. The market value of their outstanding shares is at $43.4 million. </li>
<li>Avenue Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) shares moved upwards by 6.46% to $0.16. The company's market cap stands at $6.9 million. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) shares increased by 5.34% to $1.38. The company's market cap stands at $47.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Apyx Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APYX#NASDAQ">APYX</a>) shares declined by 6.1% to $1.38 during Tuesday's after-market session. The company's market cap stands at $47.8 million. </li>
<li>NKGen Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) shares decreased by 6.11% to $1.23. The market value of their outstanding shares is at $27.5 million. </li>
<li>Molecular Templates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) shares decreased by 5.95% to $1.74. The market value of their outstanding shares is at $11.4 million. </li>
<li>Medigus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGS#NASDAQ">MDGS</a>) stock declined by 5.62% to $2.52. The company's market cap stands at $4.7 million. </li>
<li>Novo Integrated Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVOS#NASDAQ">NVOS</a>) shares declined by 5.18% to $0.5. The market value of their outstanding shares is at $8.9 million. </li>
<li>Avalo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>) stock fell 4.98% to $13.76. The company's market cap stands at $14.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APYX

ATXI

AVTX

ICCC

JAGX

LIFE

MDGS

MTEM

NKGN

NVOS

12 Health Care Stocks Moving In Tuesday's After-Market Session

Atopic dermatitis is the first immune disease indication being studied in the clinic for soquelitinib, the Company's selective ITK inhibitor &nbsp;
Corvus anticipates releasing initial clinical data from trial before year-end 2024

Corvus Pharmaceuticals Announces Initiation Of Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis

Cantor Fitzgerald analyst Li Watsek reiterates Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) with a Overweight.

Reiteration

Cantor Fitzgerald Reiterates Overweight on Corvus Pharma

Mizuho analyst Graig Suvannavejh maintains Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) with a Neutral and maintains $3.5 price target.

Mizuho Maintains Neutral on Corvus Pharma, Maintains $3.5 Price Target

Corvus Pharmaceuticals Is Ready To Take Flight

Corvus Pharmaceuticals files for $200M mixed securities shelf

Corvus Pharmaceuticals GAAP EPS of -$0.07 beats by $0.05

In a report released today, Jeff Jones from Oppenheimer maintained a Buy rating on Corvus Pharmaceuticals (CRVS – Research Report), with a price ta...

Oppenheimer Sticks to Its Buy Rating for Corvus Pharmaceuticals (CRVS)

Corvus Pharmaceuticals, Inc. (CRVS) Q2 2024 Earnings Call Transcript

Corvus Pharmaceuticals, Inc. 2024 Q2 - Results - Earnings Call Presentation

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Corvus Pharmaceuticals (CRVS – Research Report), V...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Corvus Pharmaceuticals (CRVS), Vir Biotechnology (VIR) and Cooper Co (COO)

Corvus Pharmaceuticals: Soquelitinib's High Stakes In PTCL Therapy

Corvus Pharmaceuticals Eyes Phase 3 Trials: Soquelitinib's Promise In PTCL

Corvus spikes as late-stage trial for lead asset announced

ABBV

REGN

Press Releases

Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results

Health Care

Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference

Publication of Preclinical Data in Science Signaling Demonstrated the Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Treatment of Inflammatory Diseases

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024

Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

Kaskela Law LLC Announces Shareholder Investigation of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) and Encourages Investors to Contact the Firm

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Corvus Pharma

Corvus Pharma (CRVS) Forecast

Corvus Pharma (NASDAQ:CRVS) Stock, Quote.Headers.trade-ideas